The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization for a vaccine to combat the spread of coronavirus (COVID-19) vaccine through emergency use authorization. During the approval process, members of the FDA committee expressed concern regarding adverse reactions to the vaccine. The FDA reports the most common solicited adverse reactions were injection site reactions, fatigue, headache, muscle pain, chills, joint pain, and fever. The FDA has noted the vaccine will be provided with a warning against administering it to anyone with a history of severe allergic reactions to vaccines or allergies to any of the ingredients of the vaccine.

View Article

The above publication is saved in PDF format. You will need the free Adobe Acrobat Reader to view this document.